IMC Chicago LLC Makes New $423,000 Investment in AxoGen, Inc. $AXGN

IMC Chicago LLC bought a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 4th quarter, HoldingsChannel.com reports. The fund bought 12,935 shares of the medical equipment provider’s stock, valued at approximately $423,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Aquatic Capital Management LLC boosted its position in shares of AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 1,269 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of AxoGen during the third quarter worth $43,000. Tower Research Capital LLC TRC boosted its position in shares of AxoGen by 189.9% during the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 3,327 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of AxoGen during the third quarter worth $64,000. Finally, State of Wyoming purchased a new position in shares of AxoGen during the second quarter worth $69,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Performance

Shares of AXGN stock opened at $43.48 on Thursday. The stock has a market capitalization of $2.31 billion, a PE ratio of -67.94 and a beta of 1.17. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $45.83. The stock’s 50-day moving average price is $33.98 and its 200 day moving average price is $30.97. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08.

AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The business had revenue of $61.46 million for the quarter, compared to analyst estimates of $57.85 million. As a group, equities research analysts forecast that AxoGen, Inc. will post -0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. HC Wainwright raised their price target on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Lake Street Capital raised their price target on AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Citigroup reissued an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Citizens Jmp boosted their target price on AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company boosted their target price on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, AxoGen has an average rating of “Moderate Buy” and an average target price of $46.50.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $50 price target, signaling continued conviction in AxoGen’s multi-year recovery and upside vs. the current market price. MarketBeat AXGN Report
• Positive Sentiment: The firm raised its FY2027 outlook to +$0.44 EPS and published a path of quarterly profitability in 2027 (Q1 2027 $0.05; Q2 $0.09; Q3 $0.14; Q4 $0.16), indicating expectations for margin improvement and stronger revenue/volume execution next year.
• Positive Sentiment: HC Wainwright nudged some near-term quarter estimates higher (notably Q3 2026 to $0.02 and Q4 2026 to $0.04), suggesting improving operational momentum late in 2026.
• Neutral Sentiment: The analyst model now provides a detailed multi-quarter cadence (Q2–Q4 2026 and Q1–Q4 2027), which gives investors a clearer roadmap but increases focus on upcoming quarters as catalysts.
• Negative Sentiment: HC Wainwright materially cut FY2026 guidance — from a prior -$0.08 to -$0.32 — signaling a weaker near-term outlook and pushing expected profitability further into 2027. This downgrade increases short-term execution risk for the stock.
• Negative Sentiment: The firm lowered Q2 2026 to -$0.02 (from -$0.01), reflecting specific near-term softness. Combined with the FY2026 cut, these adjustments are likely weighing on the shares today.
• Negative Sentiment: Recent company results showed an EPS miss (reported $0.07 vs. $0.12 consensus) despite a revenue beat, which keeps investor focus on margin recovery and makes guidance/forecasts more influential on price action.

Insider Transactions at AxoGen

In other AxoGen news, insider Erick Wayne Devinney sold 5,221 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $32.84, for a total transaction of $171,457.64. Following the transaction, the insider owned 262,781 shares of the company’s stock, valued at $8,629,728.04. This represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 2.78% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.